Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are 18 years or older with a clinical or genetic diagnosis of FAP or attenuated FAP.~* Presence of duodenal polyps with a sum of diameters ≥ 5mm.~* Minimum of two weeks since any major surgery~* WHO performance status ≤1~* Adequate bone marrow function as show by: normal leukocyte count, platelet count ≥ 120 x 109/L, Hgb \> 12 g/dL~* Adequate liver function as shown by: normal serum bilirubin(≤ 1.5 Upper Limit Normal {ULN}) and serum transaminases (≤ 2.0 ULN)~* Patient must discontinue taking any Nonsteroidal anti-inflammatory drugs (NSAIDS) within one month of treatment initiation.~* Patients must be able to provide written informed consent.~Exclusion Criteria:~* Prior treatment with any investigational drug within the preceding 4 weeks.~* Malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skins.~* Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study as determined by the Principal Investigator such as:~  1. Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia~ 2. Severely impaired lung function~ 3. Any active (acute or chronic) or uncontrolled infection/ disorders.~ 4. Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy~ 5. Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis~* Screening clinical laboratory values that indicate any of the following:~  1. anemia~ 2. thrombocytopenia~ 3. leucopenia~ 4. elevations of transaminases greater than 2X ULN~ 5. elevation of bilirubin \> 1.5 X ULN~ 6. alkaline phosphatase elevation \> 1.5 X ULN~ 7. increased creatinine, urinary protein, or urinary casts outside the clinically normal range.~* Gastrointestinal bleeding (symptoms including dyspnea, fatigue, angina, weakness, malaise, melena, hematochezia, hematemesis, anemia or abdominal pain will require clinical assessment to rule out gastrointestinal bleeding).~* Patient who is currently taking any anti-coagulation medication.~* Women who are pregnant or breast feeding.~* Patients with a known hypersensitivity to sulindac or erlotinib or to their excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Erlotinib and Sulindac (Type: ACTIVE_COMPARATOR): Erlotinib 75 mg per day in combination with sulindac 150 mg twice daily for 6 months.
- Placebo A and Placebo B (Type: PLACEBO_COMPARATOR): Placebo capsules matching erlotinib active comparator (Placebo A) once daily and placebo capsules matching sulindac active comparator (Placebo B) twice daily for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).